refractory cutaneous uclers
Conditions
Interventions
<
platelet-rich plasma>
We administer PRP(1-several cc)to the wound in a single dose according to size of the wounded area and evaluate effect of treatment at 1,2,4,6 and 8 weeks after initiation of the therapy. Additional a
s consent after start of therapy depending on a state of the wounded area every two weeks. As for the observation and the duration of treatment, we do it with eight weeks, but extend this period to li
Sponsors
Kanazawa University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Patients aged 18 over or older at informed consent.Written informed consent. 2)Patient with intractable cutaneous ulcer without the improvement or with the exacerbation by a conventional therapy. 3)Patients who have difficulty in treatment with surgery due to physical states. 4)Patients during ambulatory care,
Exclusion criteria
Exclusion criteria: 1) Patients with severe anemia (7 g/dl of Hb or less) 2)Patients with thrombocytopenia(less than Plt 150,000/ul) 3)Other patients judged by the investigator to be inappropriate as subjects of this study. 4)The hospitalized patients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to wound closure (days) We evaluate the length of time (days) from the administration of PRP to full-epithelialization or to when the wound become closed by a simple surgical closure. | — |
Secondary
| Measure | Time frame |
|---|---|
| We evaluate side reaction such as wound healing delayed, excessive inflammation about treatment with platelet-rich plasma. | — |
Countries
Japan
Contacts
Public ContactAkito Komuro
Kanazawa University Division of Plastic and Reconstructive Surgery,Department of Dermatology
Outcome results
None listed